Related Experiment Videos
Hemostatic abnormalities in multiple myeloma and related disorders
1Bowyer Oncology Center, University of California, School of Medicine, Los Angeles.
Hematology/Oncology Clinics of North America
|December 1, 1992
Summary
Patients with B-cell disorders and high paraproteins often experience bleeding due to hemostatic defects. Treatment focuses on the underlying disease, with additional therapies available for complex cases.
Area of Science:
- Hematology
- Oncology
- Internal Medicine
Background:
- B-cell disorders, including multiple myeloma and Waldenström's macroglobulinemia, can be associated with high serum paraproteins.
- These paraproteins can lead to unique hemostatic disorders, primarily predisposing patients to hemorrhage.
Purpose of the Study:
- To outline the hemostatic complications associated with paraproteinemias.
- To discuss the mechanisms underlying these bleeding risks.
- To review therapeutic strategies for managing these disorders.
Main Methods:
- Review of literature concerning paraproteinemias and hemostatic dysfunction.
- Analysis of mechanisms including acquired von Willebrand syndrome, platelet defects, and factor deficiencies.
- Summary of treatment modalities for bleeding and, less commonly, thrombotic complications.
Main Results:
- Common hemostatic defects include acquired von Willebrand syndrome, impaired platelet function, Factor X deficiency, and amyloidosis-related tissue fragility.
- Thrombocytopenia and fibrin function abnormalities also contribute to hemorrhage.
- Thrombotic complications are less frequent but can occur, particularly with lupus anticoagulant presence.
Conclusions:
- Hemostatic disorders are a significant concern in patients with paraproteinemias, often leading to bleeding.
- Management requires addressing the underlying B-cell disorder, supplemented by specific interventions as needed.
- Awareness of both hemorrhagic and thrombotic risks is crucial for patient care.